This ATLAS presents in appended form the complete monographic study on the subject. The idea is to bring the results out of the "heavier" didactic format required for the scientific presentation and at the same time to systematize all the information needed for the subsequent clinical research. The present excerpt from monographic work seeks to introduce the possibility that oncological diseases become chronic (like diabetes). The theoretical basis on which we refer is the fact that cancer cells feed only on carbohydrates. In turn, there is evidence that some nitrile glycosides have anti-cancer properties. The study is divided into four parts presented in the form of goals. Proceeding from the particular to the general, the fine molecular structure and all possible biochemical reactions of Amygdalin are examined. By itself, it is highly toxic to the physiologically active animal cell. Amygdalin has NO pronounced antitumor properties. In the first goal, he examines precisely the acceptable form for admission. It is concluded that the active anticancer molecular form is a stoichiometric mixture of the amide and carboxyl derivative of the nitrile glycoside. The second goal is to study the exact action of the anti-tumor product already introduced. After an extremely precise biochemical and mathematical analysis, a series of biochemical cycles of the exact passage of the product through the digestive system, penetration into the blood, approach to cancer cells and selective passage through their cell membrane have been deduced. The third goal is to define the chemical and pharmaceutical molecular forms. 54 methodological and/or pharmaceutical models with hundreds of variables for each are reviewed and analyzed here. The fourth goal (it is this purpose that is separately brought out in this edition) presents the interpretable prediction of anticancer susceptibility of glycosidic amides. The affinities of the pharmaceutical form to each known cancer cell line are reviewed. The results surpass many times all anti-cancer drugs and with significantly reduced toxicity. In an additional part, a generalized clinical control is presented. When conducting the treatment, it is also vitally important to not divert the therapy process to irreversible pathology. Result: The cancer can become chronic and become a practically curable disease., The theoretical basis is based on - https://doi.org/10.5281/zenodo.7295357 | Full calculations are posted here*: https://doi.org/10.5281/zenodo.7550371 | *- the information is constantly updated - choose the current version at the moment, {"references":["Cadow, J., Born, J., Manica, M., Oskooei, A., & Martínez, M. R. (2020). PaccMann: a web service for interpretable anticancer compound sensitivity prediction. Nucleic Acids Research, 48(W1), W502-8. doi:10.1093/nar/gkaa327","Christopher, A. (2017). Drawing conclusions from data: descriptive statistics, inferential statistics, and hypothesis testing, In Interpreting and using statistics in psychological research. SAGE Publications Inc. doi:10.4135/9781506304144","Dimitrov, S. D., Diderich, R., Sobanski, T., Pavlov, T. S., Chankov, G., Chapkanov, A., . . . Mekenyan, O. (2016). QSAR Toolbox – workflow and major functionalities. SAR and QSAR in Environmental Research, 27(3), 203-19. doi:10.1080/1062936X.2015.1136680","Gary, W. C., Zhengyin, Y., Wensheng, L., & Masucci, A. (2012). The IC50 Concept Revisited. Current Topics in Medicinal Chemistry, 12(11). doi:10.2174/156802612800672844","Ghandi, M., Huang, F. W., & Jané-Valbuena, J. (2019). Next-generation characterization of the Cancer Cell Line Encyclopedia. Nature, 569, 503-8. doi:10.1038/s41586-019-1186-3","Hubert, M., & Vandervieren, E. (2008). An adjusted boxplot for skewed distributions. Computational Statistics & Data Analysis, 52(12), 5186-201. doi:10.1016/j.csda.2007.11.008","Marmolejo-Ramos, F., & Tian, T. (2010). he shifting boxplot. A boxplot based on essential summary statistics around the mean. International Journal of Psychological Research, 3(1), 37-45. doi:10.21500/20112084.823","Sebaugh, J. L. (2011). Guidelines for accurate EC50/IC50 estimation. Pharmaceutical Statistics, 10, 128-34. doi:10.1002/pst.426","Soares, J., Greninger, P., Yang, W., Edelman, E. J., Lightfoot, H., Forbes, S., . . . Garnett, M. (2013). Genomics of Drug Sensitivity in Cancer: a resource for therapeutic biomarker discovery in cancer cells. Nucleic Acids Research, 41(D1), D955-61. doi:10.1093/nar/gks1111","Tsanov, V., Tsanov, H., Theoretical Analysis for the Safe Form and Dosage of Amygdalin Product, Anti-Cancer Agents in Medicinal Chemistry 2020; 20(7), DOI: 10.2174/1871520620666200313163801","Tsanov, V., Tsanov, H., Theoretical Analysis of Anticancer Cellular Effects of Glycoside Amides, Anti-Cancer Agents in Medicinal Chemistry 2022; 22(6), DOI: 10.2174/1871520621666210903122831","Tsanov, V., Tsanov, H., Theoretical Study of the Process of Passage of Glycoside Amides through the Cell Membrane of Cancer Cell, Anti-Cancer Agents in Medicinal Chemistry 2021; 21(12), DOI: 10.2174/1871520620999201103201008","Tsanov, V.; Tsanov, H.,Theoretical study of anticancer activity of glycoside amides [ third supplemented edition ], pp. 857, ISBN: 978-619-91534-4-4, DOI: 10.5281/zenodo.7295357","Yordanova, D., Schultz, T., Kuseva, C., Tankova, K., Ivanova, H., Dermen, I., . . . Mekenyan, O. (2019). Automated and standardized workflows in the OECD QSAR Toolbox. Computational Toxicology, 10, 89-104. doi:10.1016/j.comtox.2019.01.006"]}